A benchtop DNA sequencer developed by the U.S. DNA sequencing company Element Biosciences, Inc., has seen sales grow by triple digits and has received more than 100 orders since its launch in March 2022.
In this interview, NewsMedical speaks with Jeff Hawkins, CEO of Quantum-Si, about the challenges of conventional proteomic methods, as well as how next-generation protein sequencing is democratizing protein sequencing.
Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease.